Patents Examined by David W Berke-Schlessel
  • Patent number: 11987806
    Abstract: The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: May 21, 2024
    Assignee: Cellum Biomedical, Inc.
    Inventor: Richard C. Jin
  • Patent number: 11987807
    Abstract: Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: May 21, 2024
    Assignee: The General Hospital Corporation
    Inventors: Jayaraj Rajagopal, Hongmei Mou
  • Patent number: 11986500
    Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
    Type: Grant
    Filed: December 18, 2023
    Date of Patent: May 21, 2024
    Assignee: REBIOTIX INC
    Inventor: Edwin J. Hlavka
  • Patent number: 11985969
    Abstract: This disclosure describes a cryopreservative composition and methods for storing cells. Generally, the cryopreservative composition includes a sugar component and a sugar alcohol component, and is effective for storing and recovering cells without requiring dimethyl sulfoxide (DMSO).
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 21, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Allison Hubel, Kathryn Lindsay Pollock
  • Patent number: 11981948
    Abstract: Described herein are engineered organelles comprising multi-component proteins from different species incorporated into a membrane structure with interior and exterior aspects. In one embodiment the artificial organelle incorporates one or more protein complexes that absorb optical energy and catalyze electron transfer in biochemical reactions that can be used to reduce NAD+ to NADH or analogues thereof.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: May 14, 2024
    Assignee: Ensovi, Inc.
    Inventors: Kyle A Minor, Carlo D. Montemagno, David W. Wendell
  • Patent number: 11981919
    Abstract: The present invention relates to the field of stem cells. More specifically, the invention provides methods and compositions useful for forming three-dimensional human retinal tissue in vitro. In a specific embodiment, an in vitro method for differentiating hiPSCs into three-dimensional retinal tissue comprising functional photoreceptors comprises the steps of (a) culturing the hiPSCs to form aggregates; (b) transitioning the aggregates into a neural induction medium; (c) seeding the aggregates on to extracellular matrix coated cell culture substrates; (d) replacing NIM with a chemically-defined differentiation medium; (e) detaching NR domains; (f) culturing in suspension; and (g) adding animal serum or plasma component and retinoic acid.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: May 14, 2024
    Assignee: The John Hopkins University
    Inventors: Maria Valeria Canto-Soler, Xiufeng Zhong
  • Patent number: 11980698
    Abstract: Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: May 14, 2024
    Assignees: Arizona Board of Regents on Behalf of the University of Arizona, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Jordan J. Lancaster, Steven Goldman
  • Patent number: 11976295
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: May 7, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Patent number: 11975027
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: May 7, 2024
    Assignee: ImmunityBio, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • Patent number: 11976298
    Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: May 7, 2024
    Assignee: Targazyme, Inc.
    Inventors: Stephen D. Wolpe, Leonard Miller, Lynnet Koh, Thomas E. Ichim
  • Patent number: 11970724
    Abstract: The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: April 30, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shadia Abike Oshodi, Amy S. Johnson, Shawn M. Lawrence
  • Patent number: 11965199
    Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: April 23, 2024
    Assignee: SANOFI
    Inventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
  • Patent number: 11952559
    Abstract: This present disclosure relates to novel detergent compositions comprising bacterial mannanase enzymes. The detergent compositions comprising bacterial mannanases are useful in laundry and cleaning applications wherein degradation or modification of mannan is desired. The present disclosure also relates to the use of said detergent compositions in laundry and cleaning applications as well as a method for degrading mannan.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: April 9, 2024
    Assignee: AB Enzymes Oy
    Inventors: Daniela Herbst, Susanne Wieland, Nina Mussmann, Taija Leinonen, Leena Valtakari, Michael Seefried, Kari Juntunen, Daniela Dollak, Patrick Lorenz, Jari Vehmaanperae, Pentti Ojapalo, Terhi Puranen, Kristiina Jaervinen
  • Patent number: 11952592
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: April 9, 2024
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11952603
    Abstract: A pancreatin preparation having reduced viral infectivity includes one or more pancreatin enzymes and peracetic acid (PAA). At least one pancreatin enzyme may be derived from an animal source such as a porcine pancreas gland. In a particular embodiment, the one or more pancreatin enzymes are selected from the group consisting of lipases, proteases, and amylases.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: April 9, 2024
    Assignee: SCIENTIFIC PROTEIN LABORATORIES, LLC
    Inventors: Kenneth S. Manning, Yan Wang, Dustin Nielsen, Ryan Ruf, Colin Crowley, Jon Restivo, Dana Spangenberg, Karla Anhalt, Mark Romich, Anisha Akula, Carmen Fritz
  • Patent number: 11944651
    Abstract: The present invention aims to provide an antimicrobial and antiviral agent which comprises a naturally occurring component as an active ingredient and is effective against microbes including various classes of fungi and viruses. In one aspect of the present invention, provided is an antimicrobial and antiviral agent comprising Lactobacillus derived from Artemisia indica var. maximowiczii.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: April 2, 2024
    Assignee: Murata Manufacturing Co., Ltd.
    Inventors: Masachika Takata, Hirofumi Sunahara
  • Patent number: 11945795
    Abstract: Disclosed herein are compositions and methods useful for manufacturing SC-? cell, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: April 2, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Austin Thiel, Jihad Yasin, Evrett Thompson, Felicia J. Pagliuca
  • Patent number: 11946853
    Abstract: A apparatus for detecting cells or particles in a fluid container includes a dispenser configured to dispense at least one cell or at least one particle into a defined sub-volume of a fluid with which the fluid container is at least partially filled, and a detection apparatus configured to, in a time-coordinated manner with dispensing the at least one cell or the at least one particle by the dispenser, perform a detection in the defined sub-volume and/or in one or several sub-volumes underneath the defined sub-volume in order to sense the at least one cell or the at least one particle when entering the fluid or immediately after entering the fluid.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 2, 2024
    Assignee: cytena GmbH
    Inventors: Jonas Schoendube, Andre Gross
  • Patent number: 11944654
    Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: April 2, 2024
    Assignee: Rebiotix, Inc.
    Inventor: Edwin J. Hlavka
  • Patent number: 11940442
    Abstract: The current technology is related to methods for rapidly determining the metabolic baseline and potential of living cells. Embodiments relate to measuring the activity of each of the two major energy-generating pathways within the cell: mitochondrial respiration and glycolysis, first under baseline conditions, and again after applying a stress to the cells to demand increased energy supply. In some embodiments the stress may be applied by exposing the cells to a combination of two chemical compounds: a mitochondrial uncoupler and an ATP synthase inhibitor. In one embodiment, the metabolic energy generating activity of the mitochondrial respiration pathway is determined by measuring the rate of oxygen consumption by the living cells, and the metabolic energy generating activity of the glycolysis pathway is determined from a measurement of extracellular acidification caused by secretion of protons from the cell.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 26, 2024
    Assignee: Agilent Technologies, Inc.
    Inventors: David A. Ferrick, Brian Dranka